What it is: A weekly injectable GLP-1 hormone analog FDA approved for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy).
Research suggests: The STEP clinical trials showed an average of nearly 15% body weight reduction over 68 weeks - among the largest results ever demonstrated in a pharmaceutical weight loss trial.
Best for: Metabolic health and weight management researchers
Key thing to know: Among the most clinically studied compounds on this platform, with multiple large-scale independent RCTs and FDA approval for two distinct indications.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist , a synthetic version of a hormone your body naturally produces after eating, called glucagon-like peptide-1. GLP-1 is released by cells in your gut in response to food and plays a central role in signaling fullness, regulating insulin, and slowing digestion. Semaglutide was originally developed as a treatment for type 2 diabetes and is FDA approved under the brand names Ozempic (diabetes management) and Wegovy (chronic weight management).
Researchers have studied semaglutide extensively for weight loss, blood sugar regulation, cardiovascular risk reduction, and broader metabolic health optimization. It represents one of the most well-studied compounds in the GLP-1 class, with multiple large-scale randomized controlled trials establishing its efficacy and safety profile across diverse populations.
How it works.
GLP-1 is a natural hormone released by your gut after you eat. It signals your pancreas to produce insulin (to manage rising blood sugar), slows the rate at which your stomach empties food into the intestine (so you feel full longer), and reduces appetite signals in areas of the brain that regulate hunger , particularly the hypothalamus.
Semaglutide mimics this hormone but is engineered to last much longer in the body , approximately seven days per subcutaneous injection compared to the minutes that natural GLP-1 remains active. This sustained action produces continuous appetite suppression, prolonged satiety after meals, and stable blood sugar regulation throughout the week.
Think of it as amplifying your body's natural after-meal fullness signal and keeping it active for days rather than hours. Studies indicate that this mechanism also acts on reward pathways involved in food-seeking behavior, which may explain why research subjects report reduced cravings and changed food preferences beyond simple caloric restriction.
What the research shows.
Semaglutide has one of the strongest evidence profiles of any compound on this platform. The SUSTAIN clinical trial series , comprising multiple large Phase 3 randomized controlled trials , established its efficacy and safety in type 2 diabetes management across thousands of participants, comparing it to placebo and multiple active comparators. These trials consistently demonstrated meaningful reductions in HbA1c and body weight.
The STEP trial series specifically examined semaglutide for chronic weight management in people with obesity (without type 2 diabetes). STEP 1 showed an average 14.9% body weight reduction over 68 weeks , among the largest weight loss results ever demonstrated in a pharmaceutical trial. Subsequent STEP trials confirmed these findings across different populations, including those with cardiovascular risk factors.
The SELECT trial further demonstrated a 20% reduction in major cardiovascular events in people with obesity and established cardiovascular disease.
This is Strong evidence , multiple independent, large-scale human RCTs with consistent, replicated findings, extensive safety monitoring, and FDA approval. The evidence base is extensive and well-established in the peer-reviewed literature.
Biomarkers to review first.
Research protocols for semaglutide typically reference the following biomarkers as baseline context. Testing these before exploring this compound gives you and your healthcare provider the most relevant starting information.
What it's commonly researched with.
In research literature, semaglutide appears in comparison studies with related GLP-1 compounds and in combination research examining metabolic and longevity outcomes. The entries below represent what appears in the research literature , not combinations to pursue without medical supervision.